Evidence map›Paper›PMID 27803803›Full record

ReviewF1000Research2016

Group B

Miwako Kobayashi, Johan Vekemans, Carol J Baker, Adam J Ratner, Kirsty Le Doare, Stephanie J Schrag

Abstract readReview
In one paragraph

Review in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Epidemiology of Group BOpen forum infectious diseases · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Group B Streptococcus Infection in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.Advances in biochemical engineering/biotechnology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Miwako KobayashiNational Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, USA; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, USA.
Johan VekemansInitiative for Vaccine Research, World Health Organization, Geneva, Switzerland.
Carol J BakerDepartment of Pediatrics, Baylor College of Medicine, Houston, USA; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, USA; Center for Vaccine Awareness and Research, Texas Children's Hospital, Houston, USA.
Adam J RatnerDepartments of Pediatrics and Microbiology, New York University School of Medicine, New York, USA.
Kirsty Le DoareCentre for International Child Health, Imperial College, London, UK.
Stephanie J SchragNational Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, USA.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Globally, group B

Indexed as

Group B Streptococcuslow- and middle-income countriesmaternal vaccinationneonatal sepsisphase III trialvaccine development

Identifiers

PMID27803803
PMCPMC5070600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.